[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:acute-lymphoblastic-leukemia:npm1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Acute Lymphoblastic Leukemia","NPM1 Gene",5,[8,16,23,29,35],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06575296","Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant",[12],"Phase 1","RECRUITING","2026-08-26T02:18:40.612983Z","2026-05-05T02:43:27.843378Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07155226","Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression",[20],"Phase 1\u002FPhase 2","2026-08-26T02:15:17.167444Z","2026-05-05T02:43:27.256920Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07356154","A Study of Revumenib and Mezigdomide in People With Leukemia",[20],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:26.921862Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04065399","A Study of Revumenib in R\u002FR Leukemias Including Those With an MLL\u002FKMT2A Gene Rearrangement or NPM1 Mutation",[20],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:27.111185Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06397027","A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias",[12],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:27.100920Z"]